The PERK pathway inhibitor ISRIB [329] was able to attenuate amyloid β-induced neuronal cell death in AD [330], and was also shown to be promising for therapies targeting ALS [331] and traumatic brain injury (TBI) [332]. Here, EIF2AK3 is linked to Alzheimer disease.